These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 30468696

  • 1. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangana J, Dummer R, Cheng PF, Goldinger SM.
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
    [Abstract] [Full Text] [Related]

  • 2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [Abstract] [Full Text] [Related]

  • 3. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [Abstract] [Full Text] [Related]

  • 4. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C.
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [Abstract] [Full Text] [Related]

  • 5. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
    Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA.
    Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
    [Abstract] [Full Text] [Related]

  • 6. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C, Festino L, Vanella V, Ascierto PA.
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [Abstract] [Full Text] [Related]

  • 7. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
    Gogas H, Dummer R, Ascierto PA, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Sileni VC, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, Jan de Willem G, Sellier AT, Suissa J, Murris J, Gollerkeri A, Robert C, Flaherty KT.
    Eur J Cancer; 2021 Jul; 152():116-128. PubMed ID: 34091420
    [Abstract] [Full Text] [Related]

  • 8. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
    Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot JWB, Loquai C, Gollerkeri A, Pickard MD, Robert C.
    Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
    [Abstract] [Full Text] [Related]

  • 9. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors.
    Sullivan RJ, Weber J, Patel S, Dummer R, Carlino MS, Tan DSW, Lebbé C, Siena S, Elez E, Wollenberg L, Pickard MD, Sandor V, Ascierto PA.
    Clin Cancer Res; 2020 Oct 01; 26(19):5102-5112. PubMed ID: 32669376
    [Abstract] [Full Text] [Related]

  • 10. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
    Amagai R, Fujimura T, Kambayashi Y, Sato Y, Tanita K, Ohuchi K, Hashimoto A, Aiba S.
    J Dermatol; 2020 Jun 01; 47(6):654-657. PubMed ID: 32293049
    [Abstract] [Full Text] [Related]

  • 11. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA, Murer C, Kamarashev J, Dummer R, Goldinger SM.
    Eur J Dermatol; 2015 Apr 01; 25(2):177-80. PubMed ID: 25788221
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients.
    Indini A, Mandalà M.
    Expert Opin Drug Saf; 2020 Oct 01; 19(10):1229-1236. PubMed ID: 32857940
    [Abstract] [Full Text] [Related]

  • 13. An overview of binimetinib for the treatment of melanoma.
    Specenier P.
    Expert Opin Pharmacother; 2020 May 01; 21(7):747-754. PubMed ID: 32100585
    [Abstract] [Full Text] [Related]

  • 14. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
    Holbrook K, Lutzky J, Davies MA, Davis JM, Glitza IC, Amaria RN, Diab A, Patel SP, Amin A, Tawbi H.
    Cancer; 2020 Feb 01; 126(3):523-530. PubMed ID: 31658370
    [Abstract] [Full Text] [Related]

  • 15. An evaluation of encorafenib for the treatment of melanoma.
    Carr MJ, Sun J, Eroglu Z, Zager JS.
    Expert Opin Pharmacother; 2020 Feb 01; 21(2):155-161. PubMed ID: 31790307
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
    Di Guardo L.
    Recenti Prog Med; 2022 Jun 01; 113(6):28e-30e. PubMed ID: 35758129
    [Abstract] [Full Text] [Related]

  • 17. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN.
    Drugs Today (Barc); 2019 Apr 01; 55(4):247-264. PubMed ID: 31050693
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A, Jain P, Fradley MG, Lenihan D, Gutierrez JM, Jain C, de Lima M, Barnholtz-Sloan JS, Oliveira GH, Dowlati A, Al-Kindi S.
    Cancer Med; 2021 Jun 01; 10(12):3862-3872. PubMed ID: 33982883
    [Abstract] [Full Text] [Related]

  • 19. Real-world efficacy and safety of BRAF-targeted therapy for patients with advanced melanoma: A single-center retrospective study in Japan.
    Nakano E, Takahashi A, Ogata D, Namikawa K, Yamazaki N.
    J Dermatol; 2024 Sep 01; 51(9):1199-1207. PubMed ID: 38716655
    [Abstract] [Full Text] [Related]

  • 20. Development of encorafenib for BRAF-mutated advanced melanoma.
    Koelblinger P, Thuerigen O, Dummer R.
    Curr Opin Oncol; 2018 Mar 01; 30(2):125-133. PubMed ID: 29356698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.